Your browser doesn't support javascript.
loading
Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Marusiak, Anna A; Stephenson, Natalie L; Baik, Hayeon; Trotter, Eleanor W; Li, Yaoyong; Blyth, Karen; Mason, Susan; Chapman, Phil; Puto, Lorena A; Read, Jon A; Brassington, Claire; Pollard, Hannah K; Phillips, Chris; Green, Isabelle; Overman, Ross; Collier, Matthew; Testoni, Ewelina; Miller, Crispin J; Hunter, Tony; Sansom, Owen J; Brognard, John.
  • Marusiak AA; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Stephenson NL; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Baik H; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Trotter EW; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Li Y; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Blyth K; Colorectal Cancer and Wnt Signalling Group, The Beatson Institute for Cancer Research, Glasgow, United Kingdom.
  • Mason S; Colorectal Cancer and Wnt Signalling Group, The Beatson Institute for Cancer Research, Glasgow, United Kingdom.
  • Chapman P; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Puto LA; Salk Institute for Biological Studies, La Jolla, California.
  • Read JA; Discovery Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Brassington C; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Pollard HK; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Phillips C; Discovery Sciences, AstraZeneca, Cambridge, United Kingdom.
  • Green I; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Overman R; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Collier M; Discovery Sciences, AstraZeneca, Cheshire, United Kingdom.
  • Testoni E; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Miller CJ; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom. RNA Biology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom.
  • Hunter T; Salk Institute for Biological Studies, La Jolla, California.
  • Sansom OJ; Colorectal Cancer and Wnt Signalling Group, The Beatson Institute for Cancer Research, Glasgow, United Kingdom.
  • Brognard J; Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom. John.Brognard@cruk.manchester.ac.uk.
Cancer Res ; 76(3): 724-35, 2016 Feb 01.
Article en En | MEDLINE | ID: mdl-26637668
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Colon / Quinasas Quinasa Quinasa PAM / Sistema de Señalización de MAP Quinasas Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias del Colon / Quinasas Quinasa Quinasa PAM / Sistema de Señalización de MAP Quinasas Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article